Trailing-twelve-month (TTM) revenue is $5.25 Billion with a year-over-year growth of (3.32%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2025Period ended 2025-09-30 | $1,318,415,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-20 |
| Q1 FY2026Period ended 2025-12-31 | $1,345,046,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-05 |
| Q2 FY2026Period ended 2026-03-31 | $1,305,967,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q3 FY2026Period ended 2026-06-30 | $1,278,971,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $5,248,399,000 |
Current P/S: $2,858,723,164 market capitalization ÷ $5,248,399,000 TTM revenue = 0.54x.
Market capitalization source: FMP quote. Quote observed 2026-10-05T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q3 FY2026 (2026-06-30): $1.28B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-05T23:35:45.277Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-02.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-09-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2022-09-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-09-30 · USD | FY20212021-09-30 · USD | FY20222022-09-30 · USD | FY20232023-09-30 · USD | FY20242024-09-30 · USD | FY20252025-09-30 · USD |
|---|---|---|---|---|---|---|
| Advanced Technology Solutions | N/A | N/A | N/A | N/A | N/A | $325M |
| Clinical Services | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20172017-09-30 · USD | FY20182018-09-30 · USD | FY20192019-09-30 · USD | FY20202020-09-30 · USD | FY20212021-09-30 · USD | FY20222022-09-30 · USD |
|---|---|---|---|---|---|---|
| AUSTRALIA | $232M | $248M | $199M | $147M | $245M | $173M |
| Rest of World | $107M | $105M | $107M | $105M |
$5.25B
$5.25 Billion
(3.32%)
vs. $5.43B a year ago (TTM)
+5.21%
5 Year compound annual growth rate
1 Year
(3.32%)
3 Year
+2.87%
5 Year
+5.21%
10 Year
+8.33%
15 Year
+12.52%
20 Year
+10.63%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $5.43B | +$125.08M | +2.36% |
| 2024 | $5.31B | +$401.47M | +8.19% |
| 2023 | $4.90B | +$273.71M | +5.91% |
| 2022 | $4.63B | +$376.53M | +8.85% |
| 2021 | $4.25B | +$792.95M | +22.91% |
| 2020 |
TTM Growth
(3.32%)
3-Year CAGR
+2.87%
5-Year CAGR
+5.21%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-05T23:35:45.277Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-02.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| N/A |
| $2.1B |
| Outside the U.S. | $499M | N/A | N/A | N/A | N/A | N/A |
|---|
| Outside The United States | N/A | $699M | $764M | $689M | $657M | N/A |
|---|
| U.S. Federal Services | $1.6B | $1.9B | $2.3B | $2.4B | $2.7B | N/A |
|---|
| U.S. Services | $1.3B | N/A | N/A | N/A | N/A | N/A |
|---|
| US Services | N/A | $1.7B | $1.6B | $1.8B | $1.9B | N/A |
|---|
| $180M |
| UNITED KINGDOM | N/A | N/A | $294M | $246M | $286M | $411M |
|---|
| UNITED STATES | $1.8B | $1.7B | $2.3B | $3.0B | $3.6B | $3.9B |
|---|
| $3.46B |
| +$574.72M |
| +19.91% |
| 2019 | $2.89B | +$494.58M | +20.67% |
| 2018 | $2.39B | ($58.73M) | (2.40%) |
| 2017 | $2.45B | +$47.60M | +1.98% |
| 2016 | $2.40B | +$303.54M | +14.46% |
